SOHO 2021 Program

The Society of Hematologic Oncology's Ninth Annual Meeting is scheduled as a hybrid event on September 8-11, 2021. The focus of the 3.5-day program is cutting-edge approaches in the field of hematologic malignancies. The meeting includes a variety of educational formats including: general sessions, meet-the-professor sessions, breakfast with the expert, debates, case presentations, plenary sessions and a number of informal events.

Below you will find the SOHO 2021 Program-at-a-Glance and detailed program. Note that SOHO members have early access to session selections. To sign-up for FREE SOHO membership, go to the SOHO membership site.

Program-at-a-Glance

LEGEND | ABCL: aggressive B-cell lymphoma; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia; CT: cellular therapy; HL: Hodgkin lymphoma; IBCL: indolent B-cell lymphoma; IES: industry expert session; ISS: independent satellite symposium; MCL: mantle cell lymphoma; MDS: myelodysplastic syndromes; MPN: myeloproliferative neoplasms; MTP: meet the professor; TCL: T-cell lymphoma

Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC -5).

 

Detailed Program

TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
MEET-THE-PROFESSOR SESSION I    
6:45 AM MTP Session I: AML    
  Session Chair: Marina Konopleva    
  Familial Predisposition to AML: How Far Are We in the Understanding? Lucy A. Godley, MD, PhD The University of Chicago Medicine, Chicago, Illinois, USA
  Beyond BCL2 Inhibition: Prospects for MCL1 Inhibitors and Others Marina Konopleva, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Single Cell Profiling in AML Koichi Takahashi, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM MTP Session II: ALL    
  Session Chair: Josep-Maria Ribera    
  Approach to the Elderly Patient with ALL Sabina Chiaretti, MD, PhD Sapienza University, Rome, Italy
  Novel Transplant and Post-Transplant Options in ALL Aaron Logan, MD, PhD UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
  Use of BCL2 Inhibitors in ALL Wendy Stock, MD The University of Chicago Medicine, Chicago, Illinois, USA
6:45 AM MTP Session III: NHL    
  Session Chair: Mark Roschewski    
  Primary CNS Lymphoma Lakshmi Nayak, MD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  Prophylaxis and Management of Secondary CNS Lymphoma Mark J. Roschewski, MD National Cancer Institute, Bethesda, Maryland, USA
  Prognostication and Treatment of Burkitt Lymphoma in the Modern Era Adam J. Olszewski, MD Alpert Medical School of Brown University, Providence, Rhode Island, USA
6:45 AM MTP Session IV: NHL    
  Session Chair: Philippe Armand    
  Relapsed/Refractory T-cell Lymphoma Pierluigi Porcu, MD Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
  Hodgkin Lymphoma: What to Do When Checkpoint Inhibitors Fail Philippe Armand, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  POD24 in Follicular Lymphoma: What Time has Taught Us Nathan H. Fowler, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM MTP Session V: CML    
  Session Chair: Michael Deininger    
  Response and Progression in CML Jerald P. Radich, MD University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  Importance of BCR-ABL Transcript Type in CML Nick Cross, MA, PhD, FRCPath University of Southampton, Salisbury, United Kingdom
  New Drugs, New Challenges in CML Jorge Cortés, MD Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
6:45 AM MTP Session VI: MPN    
  Session Chair: Andreas Reiter    
  Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Diagnosis Annette S. Kim, MD, PhD, FCAP Brigham and Women’s Hospital, Boston, Massachusetts, USA
  Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment Andreas Reiter, MD University Medical Center Mannheim, Mannheim, Germany
  Chronic Eosinophilic Leukemia: Diagnosis and Therapy Jason R. Gotlib, MD, MS Stanford University, Stanford, California, USA
6:45 AM MTP Session VII: MDS    
  Session Chair: Guillermo Montalban-Bravo    
  A Primer on the Biology of MDS Simona Colla, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Update on CMML Guillermo Montalban-Bravo, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Update on Clonal Hematopoiesis Kelly Bolton, MD, PhD Washington University School of Medicine, St. Louis, Missouri, USA
6:45 AM MTP Session VIII: MM    
  Session Chair: Sagar Lonial    
  Other Plasma Cell Disorders  
  Novel Agents for Waldenstrom's Macroglobulinemia Jorge J. Castillo, MD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  How to Recognize and Treat MGRS Nelson Leung, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
  Bone Disease in MM Matthew T. Drake, MD, PhD Mayo Clinic Rochester, Rochester, Minnesota, USA
6:45 AM MTP Session IX: CLL    
  Session Chair: Florence Cymbalista    
  Case Studies in CLL  
  2 Case studies CLL Nicole Lamanna, MD Columbia University and at New York Presbyterian Hospital, New York, New York, USA
  2 Case studies CLL John M. Burke, MD US Oncology, Aurora, Colorado, USA
  2 Case studies CLL Deborah M. Stephens, DO The University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, USA
6:45 AM MTP Session X: CT    
  Session Chair: Renier Brentjens    
  Cellular Therapies for Solid Tumors  
  TILS for Melanoma Omid Hamid, MD Cedars-Sinai, The Angeles Clinic and Research Institute, Los Angeles, California, USA
  CARS for Solid Tumors Roisin E. O'Cearbhaill, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
  CARS for Prostate Cancer Saul Priceman, PhD City of Hope National Medical Center, Duarte, California, USA
7:45 AM BREAK    
MEET-THE-PROFESSOR SESSION II    
8:00 AM MTP Session XI: AML    
  Session Chair: Tapan Kadia    
  How Can We Improve on MRD Assessment by Flow Cytometry Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath The University of Birmingham, Birmingham, United Kingdom
  Menin Inhibitors in AML, What are the Prospects? Eunice Wang, MD Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
  Novel Strategies to Treat Elderly with AML Tapan M. Kadia, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session XII: ALL    
  Session Chair: Hervé Dombret    
  Chemotherapy Free Regimens in ALL Matthew Wieduwilt, MD, PHD OU Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
  Approach to Philadelphia Chromosome Positive ALL Partow Kebriaei, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Chemoresistance and Drug Profiling in ALL Beat C. Bornhauser, PhD University Children’s Hospital Zurich, Zurich, Switzerland
8:00 AM MTP Session XIII: NHL    
  Session Chair: Pier Luigi Zinzani    
  Tailoring Therapy in Waldenstrom Macroglobulinemia Jorge J. Castillo, MD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  New Agents in Marginal Zone Lymphoma Pier Luigi Zinzani, MD, PhD University of Bologna, Bologna, Italy
  Case Discussion in Rarer Subtypes of Indolent B-Cell Lymphoma Izidore Lossos, MD University of Miami, Miami, Florida, USA
8:00 AM MTP Session XIV:NHL    
  Session Chair: Jeremy Abramson    
  Update on CD19-Directed CAR T-Cell Therapy in B-Cell Lymphoma Federick Locke, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
  Novel Cellular Therapies in Development for Lymphoma Barbara Savoldo, MD, PhD University of North Carolina Health, Chapel Hill, North Carolina, USA
  Managing B-Cell Lymphoma Post CAR T-Cell Therapy Jeremy S. Abramson, MD Massachusetts General Hospital, Boston, Massachusetts, USA
8:00 AM MTP Session XV: CML    
  Session Chair: Jerry Radich    
  Genomically Guided Therapy in CML Timothy P. Hughes, MD, FRACP, FRCPA South Australian Health and Medical Research Institute, Adelaide, Australia
  Blast Crisis CML Michael Deininger, MD, PhD Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
  Molecular Testing of CML Patients in 2021: Between Old and New Tools Simona Soverini, MD University of Bologna, Bologna, Italy
8:00 AM MTP Session XVI: MPN    
  Session Chair: Andreas Reiter    
  Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Diagnosis Annette S. Kim, MD, PhD, FCAP Brigham and Women’s Hospital, Boston, Massachusetts, USA
  Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment Andreas Reiter, MD University Medical Center Mannheim, Mannheim, Germany
  Chronic Eosinophilic Leukemia: Diagnosis and Therapy Jason R. Gotlib, MD, MS Stanford University, Stanford, California, USA
8:00 AM MTP Session XVII: MDS    
  Session Chair: Rami Komrokji    
  Treatment of Lower Risk MDS Rami Komrokji, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
  How Do I Treat: Higher Risk MDS Andrew Brunner, MD Massachusetts General Hospital, Boston, Massachusetts, USA
  Use of Oral Hypomethylating Agents in MDS Guillermo Garcia-Manero, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session XVIII: MM    
  Session Chair: Suzanne Lenztsch    
  Non-BCMA Immunotherapy in MM  
  Next Generation CD38 Antibodies and Antibodies with Novel Targets GPRC5D and FcRH5 Thomas G. Martin, MD University of California San Francisco, San Francisco, California, USA
  Next Generation Cellular Therapies: NK Cells, AlloCARs, Vaccines, etc. Nina Shah, MD University of California San Francisco, San Francisco, California, USA
  Infection in the CD38 and Anti-BCMA Era: Prevention and Treatment Noopur Raje, MD Massachusetts General Hospital, Boston, Massachusetts, USA
8:00 AM MTP Session XIX: CLL    
  Session Chair: Paolo Ghia    
  Relapsed and Refractory CLL  
  Resistance to BCL-2i Constantine S. Tam, MBBS, MD Peter MacCallum Cancer Centre, Victoria, Australia
  Resistance to BTKi Jennifer A. Woyach, MD Ohio State University, Columbus, Ohio, USA
  Cell Based Therapy Thomas Kipps, MD, PhD University of California, San Diego, California, USA
8:00 AM MTP Session XX: CT    
  Session Chair: Sergio Giralt    
  Late Toxicities of Cellular Therapies  
  Chronic GVHD - New Therapies Daniel R. Couriel, MD, MS University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA
  CAR Induced Cytopenia Tania Jain, MBBS, MD John Hopkins University, Baltimore, MD, USA
  Long Term Follow up of CAR T Recipient Marcela V. Maus,M.D.,Ph.D. Massachusetts General Hospital, Boston, Massachusetts, USA
9:00 AM BREAK    
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA    
Session Chairs: Lori Muffly and Ching-Hon Pui    
9:15 AM Welcome and Opening Remarks Susan O'Brien President, Society of Hematologic Oncology
9:25 AM Hyper CVAD in 2021: Lessons Learned and New Approaches Elias Jabbour, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:40 AM Q & A    
9:43 AM MRD in ALL: Techniques and Therapeutic Utility Lori Muffly, MD The University of Stanford, Stanford, California, USA
9:58 AM Q & A    
10:01 AM Novel CAR-T Constructs for ALL Peggy Peihua Lu, MD, PhD Hebei Yanda Lu Daopei Hospital, Hebei, China
10:16 AM Q & A    
10:19 AM Asparaginase: Understanding and Overcoming Toxicities Ibrahim T. Aldoss, MD City of Hope Comprehensive Cancer Center, Duarte, California, USA
10:34 AM Q & A    
10:37 AM Novel approaches to T-Cell ALL David T. Teachey, MD Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
10:52 AM Q & A    
10:55 AM DEBATE: Optimal Time for Blinatumomab: Is it Time for MRD? Rachel Rau, MD Baylor College of Medicine, Houston, Texas, USA
11:10 AM DEBATE: Optimal Time for CAR-T: Is it Time for MRD? Rebecca A. Gardner, MD Seattle Children's Hospital, Seattle, Washington, USA
11:25 AM Q & A    
11:31 AM Oral Abstract: TBD TBD
INDUSTRY EXPERT SESSION IA    
11:41 AM A Treatment Option for AML TBD TBD
  This activity is supported by Bristol Myers Squibb    
INDUSTRY EXPERT SESSION IB    
11:41 AM TBD  TBD TBD
  This activity is supported by ADC Therapeutics    
12:41 PM BREAK    
PLENARY SESSION I    
Session Chair: Susan O'Brien    
1:11 PM Keynote Speaker: Managing Patients Relapsed or Refractory to Targeted Therapy Jennifer R. Brown, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
       
SESSION II: MYELODYSPLASTIC SYNDROMES    
Session Chairs: Guillermo Garcia-Manero and Uwe Platzbecker    
1:31 PM New Approaches for Lower Risk MDS Uwe Platzbecker, MD Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
1:46 PM Q & A    
1:49 PM New Immunotherapy Approaches for MDS Uma Borate, MD, MS Ohio State University James Cancer Hospital, Columbus, Ohio, USA
2:04 PM Q & A    
2:07 PM NED Inhibition Lionel Adès, MD, PhD Hôpital Saint-Louis, Paris, France
2:22 PM Q & A    
2:25 PM BCL-2 Inhibition in MDS Andrew Wei, MBBS, PhD Alfred Hospital and Monash University, Melbourne, Australia
2:40 PM Q & A    
2:43 PM Targeting p53 in MDS David A. Sallman, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
2:58 PM Q & A    
3:01 PM Oral Abstract: TBD TBD TBD
3:11 PM BREAK    
SESSION III: ACUTE MYELOID LEUKEMIA    
Session Chairs: Farhad Ravandi and Brunangelo Falini    
3:41 PM IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3:56 PM Q & A    
3:59 PM NPM1 Mutated AML: From Bench to Bedside Brunangelo Falini, MD University of Perugia, Perugia, Italy
4:14 PM Q & A    
4:17 PM FLT3 mutated AML: Moving Towards Cure Alexander E. Perl, MD University of Pennsylvania, Philadelphia, Pennsylvania, USA
4:32 PM Q & A    
4:35 PM Antibody-Based Therapy in AML: Immunotoxins and Bi-specifics Amir Fathi, MD Massachusetts General Hospital, Boston, Massachusetts, USA
4:50 PM Q & A    
4:53 PM TP53 Mutated AML: New Horizons Naval Daver, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:08 PM Q & A    
5:11 PM DEBATE: Is Maintenance Therapy in AML Necessary? YES Farhad Ravandi, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:26 PM Q & A
5:26 PM DEBATE: Is Maintenance Therapy in AML Necessary? NO Jeffrey E. Lancet, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
5:41 PM Q & A    
5:47 PM Measurable Residual Disease in AML Jacqueline Cloos, PhD Amsterdam UMC, Amsterdam, The Netherlands
6:02 PM Q & A    
6:05 PM Oral Abstract: TBD
TBD
TBD TBD
6:15 PM ADJOURN    
POSTER SESSION & WELCOME RECEPTION    
6:15 PM POSTER SESSION    
6:15 PM WELCOME RECEPTION AND AWARDS    
INDEPENDENT SATELLITE SYMPOSIUM I    
8:15 PM TBD  
  This activity is supported by CTI BioPharma, Corp
   
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM II    
6:15 AM TBD
BREAKFAST WITH THE EXPERT I    
6:45 AM How I Use MRD: European and American Perspectives Othman Al-Sawaf, MD University Hospital of Cologne, Cologne, Germany
    Matthew S. Davids, MD, MMSc Dana-Farber Cancer Institute, Boston, Massachusetts, USA
7:45 AM BREAK    
SESSION IV: MYELOPROLIFERATIVE NEOPLASMS    
Session Chairs: Olatoyosi Odenike and Jason Gotlib    
8:00 AM Simple Guideline to Systemic Mastocytosis in 2021 Jason R. Gotlib, MD, MS Stanford University, Stanford, California, USA
8:15 AM Q & A    
8:18 AM Polycythemia Vera: Is it Time to Rethink Treatment? Francesco Passamonti, MD University of Insubria, Varese, Italy
8:33 AM Q & A    
8:36 AM Evolution in Prognostication in Myelofibrosis: From IPSS and DIPSS to MIPSS-70 and MYSEC-PM Laura C. Michaelis, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA
8:51 AM Q & A    
8:54 AM Accelerated Phase of MPN: What Is It and What to Do About It Olatoyosi Sobulo Odenike, MD The University of Chicago Medicine, Chicago, Illinois, USA
9:09 AM Q & A    
9:12 AM Potential New Therapeutic Approaches for Myelofibrosis Srdan Verstovsek, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:27 AM Q & A    
9:30 AM Oral Abstract: TBD TBD TBD
9:40 AM BREAK    
SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA    
Session Chairs: Alessanda Ferrajoli and Emilie Montserrat    
10:10 AM Molecular and Microenvironmental Basis of Immunodysfunction in CLL Silvia Deaglio, MD, PhD University of Turin, Turin, Italy
10:25 AM Q & A    
10:28 AM Spectrum/Management of Infections in Patients with CLL Carsten U. Niemann, MD, PhD Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
10:43 AM Q & A    
10:46 AM DEBATE: Old Prognostic Markers Still Have a Role in CLL Management Inhye Ahn, MD National Institutes of Health Clinical Center, Bethesda, Maryland, USA
11:01 AM DEBATE: Old Prognostic Markers Have No Role in CLL Management Steven Coutre, MD Stanford University School of Medicine, Stanford, California, USA
11:16 AM Q & A    
11:22 AM Approaches to Therapy of Richter Syndrome Davide Rossi, MD, PhD Institute of Southern Switzerland, Bellinzona, Switzerland
11:37 AM Q & A    
11:40 AM New Targetable Pathways Alexey V. Danilov, MD, PhD City of Hope National Medical Center, Duarte, California, USA
11:55 AM Q & A    
11:58 AM Oral Abstract: TBD TBD TBD
INDUSTRY EXPERT SESSION IIA (Non-Accredited)    
12:08 PM Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion. Focus on Adults with Polycythemia Vera Who Have an Inadequate Response TBD TBD
  This activity is supported by Incyte    
INDUSTRY EXPERT SESSION IIB (Non-Accredited)    
12:08 PM A Treatment Option for MM TBD  TBD
  This activity is supported by Bristol Myers Squibb    
PLENARY SESSION II    
Session Chair: Hagop Kantarjian    
1:38 PM Prognostication and Therapy of Essential Thrombocythemia (ET)   Ayalew Tefferi, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
Recipient of the SOHO 2021 Distinguished Lecturer Award    
SESSION VI: CHRONIC MYELOID LEUKEMIA    
Session Chairs: Simona Soverini and Michael Deininger    
1:58 PM State of the Art in CML: Update Andreas Hochhaus, MD University Medical Center Jena, Jena, Germany
2:13 PM Q & A    
2:16 PM CML and Pregnancy Elisabetta Abruzzese, MD, PhD S.Eugenio University Hospital, Rome, Italy
2:31 PM Q & A    
2:34 PM Update on TFR Ehab L. Atallah, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA
2:49 PM Q & A    
2:52 PM Managing TKI Resistance: New Options Delphine Rea, MD, PhD Hôpital Saint Louis, Paris, France
3:07 PM Q & A    
3:10 PM Case Study: Managing Cytopenias on TKI Therapy Jane F. Apperley, MBChB, MD, FRCP, FRCPath Hammersmith Hospital London Imperial College, London, United Kingdom
3:25 PM Q & A    
3:28 PM Oral Abstract: TBD TBD TBD
3:28 PM BREAK    
SESSION VII: MULTIPLE MYELOMA    
Session Chairs: Sagar Lonial and Matthew Drake    
4:08 PM Frontline Therapy for Amylodosis: Response Assessments Angela Dispenzieri, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
4:23 PM Q & A    
4:26 PM Salvage Therapy for Amyloidosis: Agents and Anti-Fibril Therapy  Suzanne Lentzsch, MD, PhD Columbia University and at New York Presbyterian Hospital, New York, USA
4:41 PM Q & A    
4:44 PM Frontline Therapy in TE NDMM: Pros and Con's; Quads, Early Transplant, Just Revlimid for Maintenance? Amrita Y. Krishnan, MD, FACP City of Hope National Medical Center, Duarte, California, USA
4:59 PM Q & A    
5:02 PM Sequencing Treatment for Early Relapse: Which Triplets and When? Maria-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain
5:17 PM Q & A    
5:20 PM Treatment of Triple Class Refractory Myeloma: Novel Agents Robert Z. Orlowski, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:35PM Q & A    
5:38 PM Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies Saad Z. Usmani, MD, FACP  Levine Cancer Institute, Charlotte, North Carolina, USA
5:53 PM Q & A    
5:56 PM BCMA Directed CAR T-Cells: Early Results and Future Directions Jesus G. Berdeja, MD Sarah Cannon Cancer Institute, Nashville, Tennessee, USA
6:11 PM Q & A    
6:14 PM Oral Abstract: TBD
TBD
TBD TBD
6:24PM ADJOURN    
INDUSTRY EXPERT SESSION III (Non-Accredited)    
6:24 PM TBD TBD TBD
  This activity is supported by Jazz Pharmaceuticals    
INDUSTRY EXPERT SESSION IV (Non-Accredited)    
7:24PM TBD TBD TBD
  This activity is supported by Genentech    
INDEPENDENT SATELLITE SYMPOSIUM III    
8:24 PM TBD
 
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM IV    
6:15 AM TBD
BREAKFAST WITH THE EXPERT II    
6:45 AM Biology and New Therapy of Myelofibrosis Moshe Talpaz, MD University of Michigan, Ann Arbor, Michigan, USA
7:45 AM BREAK    
SESSION VIII: HODGKIN LYMPHOMA    
Session Chairs: Alison Moskowitz and Ranjana Advani    
8:00 AM Integrating Novel Agents into the Treatment of Classic Hodgkin Lymphoma Ann Lacasce, MD, MMSc Dana Farber Cancer Institute, Boston, Massachusetts, USA
8:15 AM Q & A    
8:18 AM Treatment Strategies in Nodular Lymphocyte Predominant Hodgkin Lymphoma Ranjana H. Advani, MD Stanford University Medical Center, Stanford, California, USA
8:33 AM Q & A    
8:36 AM Oral Abstract: TBD TBD TBD
SESSION IX: T-CELL LYMPHOMA    
Session Chairs: Mary Jo Lechowicz and Neha Mehta-Shah    
8:46 AM New Pathways and New Targets in PTCL Ryan A. Wilcox, MD, PhD University of Michigan, Ann Arbor, Michigan, USA
9:01 AM Q & A    
9:04 AM Moving Beyond BV-CHP in PTCL Neha Mehta-Shah, MD Washington University School of Medicine, St. Louis, Missouri, USA
9:19 AM Q & A    
9:22 AM Treatment of Advanced CTCL in 2021 Lauren C. Pinter-Brown, MD UCI Health, Chao Family Comprehensive Cancer Center, Orange, California, USA
9:37 AM Q & A    
9:40 AM Immunotherapy Approaches in T-Cell Lymphoma Maksim Mamonkin, PhD Baylor College of Medicine, Houston, Texas, USA
9:55 AM Q & A    
9:58 AM Disparities in Treatment in Patients with T-Cell Lymphoma Mary Jo Lechowicz, MD Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
10:13 AM Q & A    
10:16 AM Oral Abstract: TBD TBD TBD
10:26 AM BREAK    
SESSION X: INDOLENT B-CELL LYMPHOMA    
Session Chairs: Nathan Fowler and Christopher Flowers    
10:56 AM Molecular Pathogenesis of Follicular Lymphoma and Its Relevance to Clinical Practice Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD Barts Cancer Institute, London, United Kingdom
11:11 AM Q & A    
11:14 AM Sequencing Therapy in Follicular Lymphoma Peter Martin, MD Weill Medical College of Cornell University, New York, New York, USA
11:29 AM Q & A    
11:32 AM Novel Therapies in Indolent Lymphoma Loretta Nastoupil, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:47 AM Q & A    
11:50 AM Car T-Cell Therapy in Indolent Lymphoma Caron A. Jacobson, MD, MMSc Dana-Farber Cancer Institute, Boston, Massachusetts, USA
12:05 PM Q & A    
12:08 PM Oral Abstract: TBD TBD TBD
INDUSTRY EXPERT SESSION VA (Non-Accredited)    
12:18 PM

TBD

TBD

TBD

 

This activity is supported by Janssen Biotech & Pharmacyclics, LLC

INDUSTRY EXPERT SESSION VB (Non-Accredited)    
12:18 PM A Treatment Option for Lymphoma TBD TBD
  This activity is supported by Bristol Myers Squibb    
1:18 PM BREAK    
PLENARY SESSION III    
Session Chair: Moshe Talpaz    
1:48 PM From Biology to Therapy: Progress in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Mayo Clinic Rochester, Rochester, Minnesota, USA
SESSION XI: AGGRESSIVE B-CELL LYMPHOMA    
Session Chairs: Georg Lenz and Laurie Sehn    
2:08 PM Dissecting the Biology of DLBCL: How Close Are We to a Clinically Validated Molecular Platform? Georg Lenz, MD University Hospital Münster, Münster, Germany
2:23 PM Q & A    
2:26 PM Innovative Approaches in Untreated DLBCL Jason R. Westin, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:41 PM Q & A    
2:44 PM Sequencing Therapies in Transplant-Ineligible DLBCL Laurie H. Sehn, MD, MPH BC Cancer, Vancouver, Canada
2:59 PM Q & A    
3:02 PM The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma Gilles Salles, MD, PhD Memorial Sloan Kettering Cancer Center, New York, New York, USA
3:17 PM Q & A    
3:20 PM Update on Primary Mediastinal B-Cell Lymphoma Kieron M. Dunleavy, MD Georgetown University, Washington DC, USA
3:35 PM Q & A    
3:38 PM High Grade B-Cell Lymphoma : Double/Triple Hit and NOS Andrew Davies, MD University of Southampton, Southampton, United Kingdom
3:53 PM Q & A    
3:56 PM Oral Abstract: TBD TBD TBD
4:06 PM BREAK    
SESSION XII: MANTLE CELL LYMPHOMA    
Session Chairs: Thomas Witzig and Kami Maddocks    
4:36 PM Dissecting the Biology of Mantle Cell Lymphoma: What is Clinically Relevant Thomas Witzig, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
4:51 PM Q & A    
4:54 PM Tailoring Upfront Therapy in Mantle Cell Lymphoma Brad S. Kahl, MD Washington University Medical School, St. Louis, Missouri, USA
5:09 PM Q & A    
5:12 PM Novel Treatment Approaches in Relapsed/Refractory MCL Kami J. Maddocks, MD Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA
5:27 PM Q & A    
5:30 PM CAR T-Cell Therapy in Mantle Cell Lymphoma Michael Wang, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:45 PM Q & A    
5:48 PM Oral Abstract: TBD TBD TBD
5:58 PM ADJOURN    
INDUSTRY EXPERT SESSION VI (Non-Accredited)    
5:58 PM Monjuvi (Tafasitamab-Cxix) For Use As Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide TBD TBD
  This activity is supported by Incyte and MorphoSys    
INDUSTRY EXPERT SESSION VII (Non-Accredited)    
6:58 PM TBD
   
 

This activity is supported by Genentech

INDEPENDENT SATELLITE SYMPOSIUM VI    
8:28 PM TBD
   
   
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDUSTRY SATELLITE SESSION VII    
6:15 AM TBD
BREAKFAST WITH THE EXPERT III    
6:45 AM Cell Therapy for Myeloma:
When, Where, and What Type
Sergio Giralt, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
7:45 AM BREAK    
SESSION XIII: CELLULAR THERAPY    
Session Chairs: Damian Green and Eric Smith    
8:00 AM Microbiome and CAR T Cells Melody Smith, MD, MS Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:15 AM Q & A    
8:18 AM Off the Shelf CARs Martin Pule, MB BCh, MRCP Cancer Institute, University College London, London, United Kingdom
8:33 AM Q & A    
8:36 AM Cytotoxic T Lymphocyte Therapy for Viral Infection Amanda L. Olson, MD The University of Texas at MD Anderson Cancer Center, Houston, Texas, USA
8:51 AM Q & A    
8:54 AM NYESO Targeted TCRs Adam J. Schoenfeld, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:09 AM Q & A    
9:12 AM CAR T for Pediatric ALL: What's Next? Stephan Grupp, MD, PhD University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
9:27 AM Q & A    
9:30 AM Oral Abstract: TBD TBD TBD
9:40 AM BREAK    
SESSION XIV: NEXT QUESTIONS    
Session Chairs: Susan O'Brien and Hagop Kantarjian    
10:10 AM Next Questions: Acute Lymphoblastic Leukemia Bijal Shah MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
10:20 AM Next Questions: Acute Myeloid Leukemia Hagop Kantarjian, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:30 AM Next Questions: Cellular Therapy Marcela V. Maus, MD, PhD Massachusetts General Hospital, Boston, Massachusetts, USA
10:40 AM Next Questions: Chronic Lymphocytic Leukemia Susan O'Brien, MD UCI Health Chao Family Comprehensive Cancer Center, Orange, California, USA
10:50 AM Next Questions: Chronic Myeloid Leukemia Jorge Cortés, MD Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
11:00 AM Next Questions: Aggressive B-Cell Lymphoma Grzegorz S. Nowakowski, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
11:10 AM Next Questions: Indolent B-Cell Lymphoma Judith Trotman, MBChB, FRACP, FRCPA Concord Repatriation General Hospital, Sydney, Australia
11:20 AM Next Questions: T-Cell Lymphoma Barbara Pro, MD Robert H Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA
11:30 AM Next Questions: Mantle Cell Lymphoma Martin Dreyling, MD, PhD University of Munich, Munich, Germany
11:40 AM Next Questions: Hodgkin Lymphoma Craig H. Moskowitz, MD University of Miami Health System, Miami, Florida, USA
11:50 AM Next Questions: Multiple Myeloma Ola C. Landgren, MD, PhD University of Miami Health System, Miami, Florida, USA
12:00 PM Next Questions: Myelodysplastic Syndromes Guillermo Garcia-Manero, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:10 PM Next Questions: Myeloproliferative Neoplasms Srdan Verstovsek, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:20 PM CLOSING REMARKS Susan O'Brien, MD  President, Society of Hematologic Oncology 
12:30 PM ADJOURN